Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRD119
MIFTS: 64

Cardiac Arrest

Categories: Blood diseases, Cardiovascular diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cardiac Arrest

About this section

MalaCards integrated aliases for Cardiac Arrest:

Name: Cardiac Arrest 12 76 29 55 6 43 15 73
Cardiopulmonary Arrest 12 55 73
Circulatory Arrest 12 15 73
Heart Arrest 44

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:0060319
ICD10 33 I46 I46.0
ICD9CM 35 427.5
MeSH 44 D006323
SNOMED-CT 68 30298009
Sources

Summaries for Cardiac Arrest

About this section
MedlinePlus : 43 The heart has an internal electrical system that controls the rhythm of the heartbeat. Problems can cause abnormal heart rhythms, called arrhythmias. There are many types of arrhythmia. During an arrhythmia, the heart can beat too fast, too slow, or it can stop beating. Sudden cardiac arrest (SCA) occurs when the heart develops an arrhythmia that causes it to stop beating. This is different than a heart attack, where the heart usually continues to beat but blood flow to the heart is blocked. There are many possible causes of SCA. They include coronary heart disease, physical stress, and some inherited disorders. Sometimes there is no known cause for the SCA. Without medical attention, the person will die within a few minutes. People are less likely to die if they have early defibrillation. Defibrillation sends an electric shock to restore the heart rhythm to normal. You should give cardiopulmonary resuscitation (CPR) to a person having SCA until defibrillation can be done. If you have had an SCA, an implantable cardiac defibrillator (ICD) reduces the chance of dying from a second SCA. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Cardiac Arrest, also known as cardiopulmonary arrest, is related to ventricular fibrillation, paroxysmal familial, 1 and arrhythmogenic right ventricular cardiomyopathy, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Cardiac Arrest is PLN (Phospholamban), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Neuroscience. The drugs Clonazepam and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and lung, and related phenotypes are behavior/neurological and cardiovascular system

Disease Ontology : 12 A congestive heart failure characterized by a sudden stop in effective blood circulation due to the failure of the heart to contract effectively or at all.

Wikipedia : 76 Cardiac arrest is a sudden loss of blood flow resulting from the failure of the heart to effectively... more...

Sources

Related Diseases for Cardiac Arrest

About this section

Diseases in the Cardiac Arrest family:

Post-Cardiac Arrest Syndrome

Diseases related to Cardiac Arrest via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 400)
# Related Disease Score Top Affiliating Genes
1 ventricular fibrillation, paroxysmal familial, 1 32.3 TNNT2 SCN5A RYR2 KCNQ1 DSP
2 arrhythmogenic right ventricular cardiomyopathy 32.3 DSP PLN RYR2 SCN5A
3 cardiac conduction defect 32.0 SCN5A RYR2 PLN MYBPC3 KCNQ1 DSP
4 myocardial infarction 31.9 ACE ALB CKB S100B TNNT2
5 long qt syndrome 1 31.9 TRDN SCN5A RYR2 KCNQ1 DSP CASQ2
6 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 31.5 TRDN SCN5A RYR2 KCNQ1 DSP CASQ2
7 long qt syndrome 30.4 CALM1 KCNQ1 MYBPC3 RYR2 SCN5A
8 acute myocardial infarction 30.3 ACE CKB TNNT2
9 cardiac arrhythmia 30.3 KCNQ1 RYR2 SCN5A
10 catecholaminergic polymorphic ventricular tachycardia 30.2 TRDN TECRL SCN5A RYR2 MYBPC3 CASQ2
11 hypertrophic cardiomyopathy 30.2 TNNT2 SCN5A RYR2 PLN MYBPC3 DSP
12 atrial fibrillation 30.0 ACE KCNQ1 MYBPC3 RYR2 SCN5A
13 neonatal hypoxic and ischemic brain injury 30.0 CKB ENO2
14 heart disease 29.9 TNNT2 SCN5A S100B RYR2 MYBPC3 KCNQ1
15 atrial standstill 1 29.8 TNNT2 SLC25A20 SCN5A PLN MYBPC3 DSP
16 left ventricular noncompaction 29.6 TNNT2 SCN5A RYR2 MYBPC3 KCNQ1 DSP
17 dilated cardiomyopathy 29.2 TRDN TNNT2 SCN5A RYR2 PLN MYBPC3
18 post-cardiac arrest syndrome 12.5
19 jervell and lange-nielsen syndrome 1 11.4
20 hypokalemia 11.3
21 hypoxia 11.3
22 orthostatic intolerance 11.3
23 pulmonary edema 11.3
24 cerebral hypoxia 11.3
25 wolff-parkinson-white syndrome 11.3
26 myocarditis 11.3
27 eclampsia 11.3
28 cyanide poisoning 11.3
29 cardiomyopathy, infantile histiocytoid 11.2
30 ventricular tachycardia, catecholaminergic polymorphic, 3 11.1
31 coronary artery dissection, spontaneous 11.0
32 pseudohyperkalemia, familial, 2, due to red cell leak 11.0
33 ventricular tachycardia, catecholaminergic polymorphic, 2 11.0
34 ventricular tachycardia, catecholaminergic polymorphic, 4 11.0
35 ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness 11.0
36 sudden cardiac failure, infantile 11.0
37 sudden cardiac failure, alcohol-induced 11.0
38 cardiogenic shock 10.4
39 ischemia 10.4
40 pulmonary embolism 10.3
41 familial isolated arrhythmogenic ventricular dysplasia, right dominant form 10.3 DSP RYR2
42 eosinophilia-myalgia syndrome 10.3
43 familial isolated arrhythmogenic ventricular dysplasia, biventricular form 10.3 DSP RYR2
44 idiopathic ventricular fibrillation, non brugada type 10.3 DPP6 SCN5A
45 familial isolated arrhythmogenic ventricular dysplasia, left dominant form 10.3 DSP RYR2
46 paroxysmal ventricular fibrillation 10.3 DPP6 SCN5A
47 ocular motor apraxia 10.3
48 intracranial cysts 10.3 ENO2 S100B
49 bednar tumor 10.3 ENO2 S100B
50 arrhythmogenic right ventricular dysplasia, familial, 9 10.3 DSP PLN RYR2

Comorbidity relations with Cardiac Arrest via Phenotypic Disease Network (PDN): (show all 33)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Aortic Aneurysm Aortic Valve Disease 1
Bronchitis Cardiogenic Shock
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Disseminated Intravascular Coagulation Familial Atrial Fibrillation
First-Degree Atrioventricular Block Generalized Atherosclerosis
Heart Disease Hypertension, Essential
Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome Intermediate Coronary Syndrome
Ischemic Heart Disease Kidney Disease
Mitral Valve Disease Ocular Motor Apraxia
Peripheral Vascular Disease Progressive Familial Heart Block, Type Ia
Protein-Energy Malnutrition Pulmonary Hypertension, Primary, 1
Respiratory Failure Sinoatrial Node Disease
Third-Degree Atrioventricular Block Tricuspid Valve Disease
Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Cardiac Arrest:



Diseases related to Cardiac Arrest
Sources

Symptoms & Phenotypes for Cardiac Arrest

About this section

UMLS symptoms related to Cardiac Arrest:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Cardiac Arrest:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 ACE CKB CYCS ENO2 KCNQ1 MYBPC3
2 cardiovascular system MP:0005385 9.96 ACE CASQ2 CYCS DSP KCNQ1 MYBPC3
3 growth/size/body region MP:0005378 9.9 ACE CASQ2 CKB CYCS DSP ENO2
4 muscle MP:0005369 9.61 ALB CASQ2 DSP KCNQ1 MYBPC3 RYR2
5 nervous system MP:0003631 9.32 CKB CYCS DPP6 DSP ENO2 KCNQ1
Sources

Drugs & Therapeutics for Cardiac Arrest

About this section

Drugs for Cardiac Arrest (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 757)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
2
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
3
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
4
Lorazepam Approved Phase 4,Not Applicable 846-49-1 3958
5
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
6
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
7
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
8
Ticagrelor Approved Phase 4 274693-27-5 9871419
9
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
10
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 113775-47-6 68602 5311068
11
Midazolam Approved, Illicit Phase 4,Phase 3,Not Applicable 59467-70-8 4192
12
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
13
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
14
Clopidogrel Approved Phase 4,Not Applicable 113665-84-2, 120202-66-6 60606
15
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
16
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
17
Ofloxacin Approved Phase 4 82419-36-1 4583
18
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
19 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
21
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
22
Cisatracurium Approved Phase 4 96946-41-7
23
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137-58-6 3676
24
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
25
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10102-43-9 145068
26
Mannitol Approved, Investigational Phase 4,Phase 2 69-65-8 453 6251
27
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
29
Misoprostol Approved Phase 4,Phase 1 59122-46-2 5282381
30
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-56-6 439302 53477758
31
Dobutamine Approved Phase 4,Phase 3,Not Applicable 34368-04-2 36811
32
Oxymetazoline Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1491-59-4 4636
33
Phenylephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 59-42-7 6041
34
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-41-2 439260
35
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613
36
Ticlopidine Approved Phase 4,Not Applicable 55142-85-3 5472
37
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 16590-41-3 5360515
38
Nifedipine Approved Phase 4,Phase 2 21829-25-4 4485
39
Ritodrine Approved, Investigational Phase 4 26652-09-5 33572
40
Atropine Approved, Vet_approved Phase 4,Phase 2 51-55-8, 5908-99-6 174174
41
Meperidine Approved Phase 4 57-42-1 4058
42
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
43
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3 28014-46-2
44
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
45
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-28-2 5757
46
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
47
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
48 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 979-32-8
49
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
50
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559

Interventional clinical trials:

(show top 50) (show all 1666)
# Name Status NCT ID Phase Drugs
1 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
2 Hyperinvasive Approach in Cardiac Arrest Unknown status NCT01511666 Phase 4
3 Therapeutic Hypothermia With Propofol in Survival and Neurological Prognoses After Cardiac Arrest Unknown status NCT02367755 Phase 4 Propofol;Lorazepam
4 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4 sodium bicarbonate
5 Trial of IV NTG for CD After Second Stage Arrest for the Prevention of Uterine Extension Unknown status NCT02265965 Phase 4 intravenous nitroglycerin
6 Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome Unknown status NCT02341729 Phase 4 ticagrelor
7 Early Feeding Following Ligation of Acute Bleeding Varices Unknown status NCT01287702 Phase 4
8 Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
9 Effects of Preconditioning With Sevoflurane During Organ Procurement From Brain Dead Donors: Impact on Early Function of Liver Allografts Unknown status NCT02341833 Phase 4 Sevoflurane
10 CERAMENTâ„¢|G - Bone Healing and Re-infection Prophylaxis Unknown status NCT02128256 Phase 4
11 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
12 Role of FSHR Polymorphism p.N680S in the Therapy With FSH in Patients Who Underwent Varicocele Surgery Unknown status NCT02719093 Phase 4 recombinant FSH
13 Safety and Efficacy of Intranasal Dexmedetomidine Unknown status NCT02985697 Phase 4 Dexmedetomidine;Midazolam Hydrochloride;Nitrous Oxide
14 Assess the Penumbra System in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
15 Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism Unknown status NCT02029456 Phase 4 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
16 Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery Unknown status NCT02672813 Phase 4
17 The Effect of Chest Tubes Using Active Clearance Technology® on the Incidence of Postoperative Atrial Fibrillation Unknown status NCT02808897 Phase 4
18 Prophylactic Antibiotics in Comatose Survivors of Out-of-hospital Cardiac Arrest Completed NCT02899507 Phase 4 Amoxicillin-Clavulanic acid
19 Continuous Chest Compressions vs AHA Standard CPR of 30:2 Completed NCT01372748 Phase 4
20 Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest Completed NCT00127907 Phase 4 epinephrine (1 mg/1 mL);arginine-vasopressin (40 UI/2 mL)
21 Intraosseous vs Intravenous Access for Cardiac Arrest Treatment Completed NCT02088736 Phase 4
22 Comparing Therapeutic Hypothermia Using External and Internal Cooling for Post-Cardiac Arrest Patients Completed NCT00827957 Phase 4
23 Clinical and Economical Interest of Endovascular Cooling in the Management of Cardiac Arrest (ICEREA Study) Completed NCT00392639 Phase 4
24 Antiplatelet Therapy After Cardiac Arrest Completed NCT02224274 Phase 4 Clopidogrel;Ticagrelor
25 Trial of Different Hypothermia Temperatures in Patients Recovered From Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
26 COOL-Trial: Outcome With Invasive and Non-invasive Cooling After Cardiac Arrest Completed NCT00843297 Phase 4
27 Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest Completed NCT01369732 Phase 4 recombinant human erythropoietin;saline
28 Cardiopulmonary Resuscitation Witnessing by a Relative Completed NCT01009606 Phase 4
29 Beating Versus Arrested Heart for Mitral Valve Replacement Completed NCT01641614 Phase 4
30 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
31 Quick ICD Study: Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary ? Completed NCT00180362 Phase 4
32 Transthoracic Incremental Monophasic Versus Biphasic by Emergency Responders (TIMBER) Completed NCT00101881 Phase 4
33 The Effect of Silver Diamine Fluoride (SDF) on Bacteria Involved in Root or Cervical Carious Lesions Completed NCT02953886 Phase 4
34 Randomized Trial of Pulsatile vs Non Pulsatile Perfusion on Short Term Changes in Kidney Function Using an Intra-Aortic Ballooon Pump During Cardioplegic Arrest in Patients Undergoing Myocardial Reperfusion Completed NCT00454428 Phase 4
35 Comparative Study Between Nifedipine and Ritodrine as Maintenance Tocolytic Therapy in Preterm Labor Completed NCT03040752 Phase 4 Nifedipine 20 Mg;Ritodrine Oral Tablet
36 ISSUE3: International Study on Syncope of Uncertain Etiology 3 Completed NCT00359203 Phase 4
37 Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy Completed NCT00575523 Phase 4 Atropine;Placebo
38 The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial Completed NCT00430989 Phase 4 Nitrous Oxide;Nitrous Oxide
39 Study of the Effectiveness of Administration of Meperidine on the Length of Active Phase of Labor in Women Completed NCT01555671 Phase 4 Placebo;Meperidine
40 Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD Completed NCT00159835 Phase 4 atorvastatin;simvastatin
41 Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia Completed NCT00665327 Phase 4 Avelox (Moxifloxacin, BAY12-8039);Levofloxacin
42 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated Completed NCT01157351 Phase 4 paliperidone;risperidone;haloperidole;perphenazine;aripiprazole;quetiapine;paliperidone palmitate;olanzapine
43 Out-of-Hospital Intubation With Metal Single Use Laryngoscope Blades Completed NCT00644722 Phase 4
44 Fluvastatin in the Therapy of Acute Coronary Syndrome Completed NCT00171275 Phase 4 Fluvastatin
45 Heart Outcomes Prevention Evaluation-3 Completed NCT00468923 Phase 4 Candesartan/HCT;Rosuvastatin
46 IRIS : Use of Implantable Defibrillator in High-risk Patients Early After Acute Myocardial Infarction Completed NCT00157768 Phase 4
47 Preventive and Therapeutic Proximal Sealants Completed NCT02338180 Phase 4
48 Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke Completed NCT00147602 Phase 4 atorvastatin
49 Evaluation of Statin Mechanism Preventing Cardiovascular Disease by Post-hoc Analysis of Treating to New Targets Study Completed NCT03073863 Phase 4 Atorvastatin
50 CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events Completed NCT00327418 Phase 4 Atorvastatin

Search NIH Clinical Center for Cardiac Arrest

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: heart arrest

Sources

Genetic Tests for Cardiac Arrest

About this section

Genetic tests related to Cardiac Arrest:

# Genetic test Affiliating Genes
1 Cardiac Arrest 29
Sources

Anatomical Context for Cardiac Arrest

About this section

MalaCards organs/tissues related to Cardiac Arrest:

41
Heart, Brain, Lung, Testes, Kidney, Liver, Spinal Cord
Sources

Publications for Cardiac Arrest

About this section

Articles related to Cardiac Arrest:

(show top 50) (show all 2309)
# Title Authors Year
1
Longitudinal exploration of in situ mock code events and the performance of cardiac arrest skills. ( 30555719 )
2019
2
Respiratory Deterioration and Cardiac Arrest. ( 30557264 )
2019
3
Update of a Systematic Review of Autoresuscitation after Cardiac Arrest: Erratum. ( 30557265 )
2019
4
Incidence of peri-operative paediatric cardiac arrest and the influence of a specialised paediatric anaesthesia team: Retrospective cohort study. ( 30048261 )
2019
5
The gradient between arterial and end-tidal carbon dioxide predicts in-hospital mortality in post-cardiac arrest patient. ( 29685358 )
2019
6
Expanded Criteria Donor-Related Hyperkalemia and Postreperfusion Cardiac Arrest During Liver Transplantation: A Case Report and Literature Review. ( 29967315 )
2018
7
Out-of-Hospital Cardiac Arrest in the Presence of Ischemic Heart Disease: What Is the Long-term Arrhythmic Risk After Revascularization? ( 29958725 )
2018
8
Outcomes and healthcare-associated costs one year after intensive care-treated cardiac arrest. ( 29958958 )
2018
9
Delphi Analysis of Science Gaps in the 2015 American Heart Association Cardiac Arrest Guidelines. ( 29960986 )
2018
10
The Use of ECMO for the Treatment of Refractory Cardiac Arrest or Postarrest Cardiogenic Shock Following In-Hospital Cardiac Arrest: A 10-Year Experience. ( 29303029 )
2018
11
"Resuscitation time bias"-A unique challenge for observational cardiac arrest research. ( 29425975 )
2018
12
Ocular bobbing/dipping after cardiac arrest may be a post-anoxic myoclonus. ( 29307541 )
2018
13
Successful Resuscitation with Extracorporeal Membrane Oxygenation in a Case with Prolonged Cardiac Arrest. ( 29976283 )
2018
14
Is Distance to the Nearest Registered Public Automated Defibrillator Associated with the Probability of Bystander Shock for Victims of Out-of-Hospital Cardiac Arrest? ( 29433603 )
2018
15
Activation of Sigma-1 Receptor by Cutamesine Attenuates Neuronal Apoptosis by Inhibiting Endoplasmic Reticulum Stress and Mitochondrial Dysfunction in a Rat Model of Asphyxia Cardiac Arrest. ( 29424796 )
2018
16
Association Between Early Hyperoxia Exposure After Resuscitation from Cardiac Arrest and Neurological Disability: A Prospective Multi-Center Protocol-Directed Cohort Study. ( 29437118 )
2018
17
Non-invasive characterization of hemodynamics in adult out-of-hospital cardiac arrest patients soon after return of spontaneous circulation. ( 29425976 )
2018
18
Epidemiology of Pediatric Out-of-Hospital Cardiac Arrest at Schoola88- An Investigation of a Nationwide Registry in Japan. ( 29445066 )
2018
19
Looking for CO<sub>2</sub>: Exploring the Novel Finding of Low Respiratory Quotient After Cardiac Arrest. ( 29959139 )
2018
20
EEG Factors After Pediatric Cardiac Arrest. ( 29438177 )
2018
21
Severe metabolic acidosis after out-of-hospital cardiac arrest: risk factors and association with outcome. ( 29740777 )
2018
22
Survival after in-hospital cardiac arrest among cerebrovascular disease patients. ( 29789199 )
2018
23
Effects of dispatcher-assisted bystander cardiopulmonary resuscitation on neurological recovery in paediatric patients with out-of-hospital cardiac arrest based on the pre-hospital emergency medical service response time interval. ( 29960075 )
2018
24
Successful Treatment of Refractory Cardiac Arrest With I^-Blockade and Extracorporeal Life Support in a Pediatric Patient With Catecholaminergic Polymorphic Ventricular Tachycardia: A Case Report. ( 29634558 )
2018
25
The Role of Cranial Temperature in Neuroprotection by Sodium Hydrogen Sulfide After Cardiac Arrest in Mice. ( 29431591 )
2018
26
Variation in Sedation and Neuromuscular Blockade Regimens on Outcome After Cardiac Arrest. ( 29979225 )
2018
27
Protective effects of nicorandil against cerebral injury in a swine cardiac arrest model. ( 29977355 )
2018
28
Late heartbeat-evoked potentials are associated with survival after cardiac arrest. ( 29447999 )
2018
29
Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study. ( 29447784 )
2018
30
Changes in left ventricular systolic and diastolic function on serial echocardiography after out-of-hospital cardiac arrest. ( 29438721 )
2018
31
Characteristics of Neighbourhoods with High Incidence of Out-of-Hospital Cardiac Arrest and Low Bystander Cardiopulmonary Resuscitation Rates in England. ( 29961881 )
2018
32
Effect of target temperature management at 32-34a8^A^C in cardiac arrest patients considering assessment by regional cerebral oxygen saturation: A multicenter retrospective cohort study. ( 29432783 )
2018
33
Sudden cardiac arrest during marathon training in a young adult with short QT syndrome. ( 29876509 )
2018
34
Dissociated Oxygen Consumption and Carbon Dioxide Production in the Post-Cardiac Arrest Rat: A Novel Metabolic Phenotype. ( 29959138 )
2018
35
Optimal platelet inhibition with cangrelor in comatose survivors of out-of-hospital cardiac arrest undergoing primary percutaneous coronary intervention. ( 29969644 )
2018
36
Atherothrombotic out-of hospital cardiac arrest: watch out for a second train. ( 29437817 )
2018
37
Survival after out-of-hospital cardiac arrest in nursing homes - A nationwide study. ( 29425977 )
2018
38
Response by Bascom and Seder to Letter Regarding Article, &amp;quot;Derivation and Validation of the CREST Model for Very Early Prediction of Circulatory Etiology Death in Patients Without ST-Segment-Elevation Myocardial Infarction After Cardiac Arrest&amp;quot;. ( 29967240 )
2018
39
Cardiac arrest and ventricular arrhythmia in adults with Ebstein anomaly and left ventricular non-compaction. ( 29305187 )
2018
40
Cyanide poisoning is a possible cause of cardiac arrest among fire victims, and empiric antidote treatment may improve outcomes. ( 29395761 )
2018
41
Perioperative Cardiac Arrest: Focus on Malignant Hyperthermia (MH): Erratum. ( 29517572 )
2018
42
Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia. ( 29437823 )
2018
43
Stability of Early EEG Background Patterns After Pediatric Cardiac Arrest. ( 29443794 )
2018
44
Survival factors of hospitalized out-of-hospital cardiac arrest patients in Taiwan: A retrospective study. ( 29420551 )
2018
45
Perioperative Cardiac Arrest: Focus on Malignant Hyperthermia (MH). ( 29461317 )
2018
46
Quantitative Assessment of Pupillary Light Reflex for Early Prediction of Outcomes After Out-of-Hospital Cardiac Arrest: A Multicentre Prospective Observational Study. ( 29958957 )
2018
47
Letter by Voicu et al Regarding Article, &amp;quot;Derivation and Validation of the CREST Model for Very Early Prediction of Circulatory Etiology Death in Patients Without ST-Segment-Elevation Myocardial Infarction After Cardiac Arrest&amp;quot;. ( 29967239 )
2018
48
Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry. ( 30528916 )
2018
49
Prognostic Impact of Acute Myocardial Infarction in Patients Presenting With Ventricular Tachyarrhythmias and Aborted Cardiac Arrest. ( 30371335 )
2018
50
Predictors of Successful Weaning from Veno-Arterial Extracorporeal Membrane Oxygenation After Coronary Revascularization for Acute Myocardial Infarction Complicated by Cardiac Arrest: A Retrospective Multicenter Study. ( 30080744 )
2018
Sources

Variations for Cardiac Arrest

About this section

ClinVar genetic disease variations for Cardiac Arrest:

6 (show top 50) (show all 70)
# Gene Variation Type Significance SNP ID Assembly Location
1 PLN NM_002667.4(PLN): c.116T> G (p.Leu39Ter) single nucleotide variant Pathogenic rs111033560 GRCh37 Chromosome 6, 118880200: 118880200
2 PLN NM_002667.4(PLN): c.116T> G (p.Leu39Ter) single nucleotide variant Pathogenic rs111033560 GRCh38 Chromosome 6, 118559037: 118559037
3 MYBPC3 NM_000256.3(MYBPC3): c.3392T> C (p.Ile1131Thr) single nucleotide variant Likely benign rs370890951 GRCh37 Chromosome 11, 47354463: 47354463
4 MYBPC3 NM_000256.3(MYBPC3): c.3392T> C (p.Ile1131Thr) single nucleotide variant Likely benign rs370890951 GRCh38 Chromosome 11, 47332912: 47332912
5 DSG2 NM_001943.4(DSG2): c.437G> T (p.Arg146Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs113451409 GRCh37 Chromosome 18, 29101120: 29101120
6 DSG2 NM_001943.4(DSG2): c.437G> T (p.Arg146Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs113451409 GRCh38 Chromosome 18, 31521157: 31521157
7 DSC2 NM_004949.4(DSC2): c.1073C> T (p.Thr358Ile) single nucleotide variant Likely benign rs139399951 GRCh37 Chromosome 18, 28662896: 28662896
8 DSC2 NM_004949.4(DSC2): c.1073C> T (p.Thr358Ile) single nucleotide variant Likely benign rs139399951 GRCh38 Chromosome 18, 31082930: 31082930
9 TTN NM_001267550.2(TTN): c.29230C> T (p.Arg9744Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs375266859 GRCh37 Chromosome 2, 179571371: 179571371
10 TTN NM_001267550.2(TTN): c.29230C> T (p.Arg9744Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs375266859 GRCh38 Chromosome 2, 178706644: 178706644
11 SCN5A NM_198056.2(SCN5A): c.1715C> A (p.Ala572Asp) single nucleotide variant Benign/Likely benign rs36210423 GRCh37 Chromosome 3, 38645378: 38645378
12 SCN5A NM_198056.2(SCN5A): c.1715C> A (p.Ala572Asp) single nucleotide variant Benign/Likely benign rs36210423 GRCh38 Chromosome 3, 38603887: 38603887
13 RYR2 NM_001035.2(RYR2): c.13759A> C (p.Ile4587Leu) single nucleotide variant Uncertain significance rs730880198 GRCh37 Chromosome 1, 237955600: 237955600
14 RYR2 NM_001035.2(RYR2): c.13759A> C (p.Ile4587Leu) single nucleotide variant Uncertain significance rs730880198 GRCh38 Chromosome 1, 237792300: 237792300
15 ANK2 NM_001148.4(ANK2): c.6206G> A (p.Arg2069His) single nucleotide variant Likely benign rs149645600 GRCh37 Chromosome 4, 114275980: 114275980
16 ANK2 NM_001148.4(ANK2): c.6206G> A (p.Arg2069His) single nucleotide variant Likely benign rs149645600 GRCh38 Chromosome 4, 113354824: 113354824
17 DSP NM_004415.3(DSP): c.2260G> A (p.Glu754Lys) single nucleotide variant Uncertain significance rs730880080 GRCh37 Chromosome 6, 7574448: 7574448
18 DSP NM_004415.3(DSP): c.2260G> A (p.Glu754Lys) single nucleotide variant Uncertain significance rs730880080 GRCh38 Chromosome 6, 7574215: 7574215
19 DSP NM_004415.3(DSP): c.2821C> T (p.Arg941Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730880082 GRCh38 Chromosome 6, 7576986: 7576986
20 DSP NM_004415.3(DSP): c.2821C> T (p.Arg941Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730880082 GRCh37 Chromosome 6, 7577219: 7577219
21 CACNA2D1 NM_000722.3(CACNA2D1): c.2264G> C (p.Ser755Thr) single nucleotide variant Benign/Likely benign rs151327713 GRCh38 Chromosome 7, 81969925: 81969925
22 CACNA2D1 NM_000722.3(CACNA2D1): c.2264G> C (p.Ser755Thr) single nucleotide variant Benign/Likely benign rs151327713 GRCh37 Chromosome 7, 81599241: 81599241
23 AKAP9 NM_005751.4(AKAP9): c.1099G> A (p.Val367Met) single nucleotide variant Likely benign rs138161478 GRCh37 Chromosome 7, 91630330: 91630330
24 AKAP9 NM_005751.4(AKAP9): c.1099G> A (p.Val367Met) single nucleotide variant Likely benign rs138161478 GRCh38 Chromosome 7, 92001016: 92001016
25 AKAP9 NM_005751.4(AKAP9): c.11378C> G (p.Ser3793Cys) single nucleotide variant Uncertain significance rs730880044 GRCh37 Chromosome 7, 91735039: 91735039
26 AKAP9 NM_005751.4(AKAP9): c.11378C> G (p.Ser3793Cys) single nucleotide variant Uncertain significance rs730880044 GRCh38 Chromosome 7, 92105725: 92105725
27 CACNB2 NM_201571.3(CACNB2): c.1122+3A> T single nucleotide variant Uncertain significance rs200174877 GRCh37 Chromosome 10, 18823159: 18823159
28 CACNB2 NM_201571.3(CACNB2): c.1122+3A> T single nucleotide variant Uncertain significance rs200174877 GRCh38 Chromosome 10, 18534230: 18534230
29 CACNB2 NM_201571.3(CACNB2): c.1558G> A (p.Gly520Ser) single nucleotide variant Likely pathogenic rs730880059 GRCh37 Chromosome 10, 18828312: 18828312
30 CACNB2 NM_201571.3(CACNB2): c.1558G> A (p.Gly520Ser) single nucleotide variant Likely pathogenic rs730880059 GRCh38 Chromosome 10, 18539383: 18539383
31 MYH6 NM_002471.3(MYH6): c.4713G> T (p.Lys1571Asn) single nucleotide variant Uncertain significance rs730880151 GRCh37 Chromosome 14, 23855770: 23855770
32 MYH6 NM_002471.3(MYH6): c.4713G> T (p.Lys1571Asn) single nucleotide variant Uncertain significance rs730880151 GRCh38 Chromosome 14, 23386561: 23386561
33 DSG2 NM_001943.4(DSG2): c.1063G> A (p.Ala355Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs201046640 GRCh37 Chromosome 18, 29110998: 29110998
34 DSG2 NM_001943.4(DSG2): c.1063G> A (p.Ala355Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs201046640 GRCh38 Chromosome 18, 31531035: 31531035
35 RYR2 NM_001035.2(RYR2): c.378T> A (p.Ser126Arg) single nucleotide variant Uncertain significance rs869025507 GRCh38 Chromosome 1, 237369602: 237369602
36 RYR2 NM_001035.2(RYR2): c.378T> A (p.Ser126Arg) single nucleotide variant Uncertain significance rs869025507 GRCh37 Chromosome 1, 237532902: 237532902
37 SCN5A NM_001099404.1(SCN5A): c.5075T> C (p.Phe1692Ser) single nucleotide variant Uncertain significance rs869025521 GRCh37 Chromosome 3, 38592788: 38592788
38 SCN5A NM_001099404.1(SCN5A): c.5075T> C (p.Phe1692Ser) single nucleotide variant Uncertain significance rs869025521 GRCh38 Chromosome 3, 38551297: 38551297
39 SCN5A NM_198056.2(SCN5A): c.559A> G (p.Thr187Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs869025517 GRCh38 Chromosome 3, 38620895: 38620895
40 SCN5A NM_198056.2(SCN5A): c.559A> G (p.Thr187Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs869025517 GRCh37 Chromosome 3, 38662386: 38662386
41 SLMAP NM_007159.4(SLMAP): c.1918+1G> A single nucleotide variant Uncertain significance rs869025527 GRCh38 Chromosome 3, 57912702: 57912702
42 SLMAP NM_007159.4(SLMAP): c.1918+1G> A single nucleotide variant Uncertain significance rs869025527 GRCh37 Chromosome 3, 57898429: 57898429
43 ANK2 NM_001148.4(ANK2): c.5509G> A (p.Ala1837Thr) single nucleotide variant Uncertain significance rs199527708 GRCh37 Chromosome 4, 114275283: 114275283
44 ANK2 NM_001148.4(ANK2): c.5509G> A (p.Ala1837Thr) single nucleotide variant Uncertain significance rs199527708 GRCh38 Chromosome 4, 113354127: 113354127
45 ANK2 NM_001148.4(ANK2): c.7458C> G (p.His2486Gln) single nucleotide variant Uncertain significance rs776972443 GRCh37 Chromosome 4, 114277232: 114277232
46 ANK2 NM_001148.4(ANK2): c.7458C> G (p.His2486Gln) single nucleotide variant Uncertain significance rs776972443 GRCh38 Chromosome 4, 113356076: 113356076
47 ANK2 NM_001148.4(ANK2): c.7577C> T (p.Ser2526Leu) single nucleotide variant Uncertain significance rs762909298 GRCh37 Chromosome 4, 114277351: 114277351
48 ANK2 NM_001148.4(ANK2): c.7577C> T (p.Ser2526Leu) single nucleotide variant Uncertain significance rs762909298 GRCh38 Chromosome 4, 113356195: 113356195
49 DSP NM_004415.3(DSP): c.2047G> A (p.Glu683Lys) single nucleotide variant Uncertain significance rs775181391 GRCh37 Chromosome 6, 7572218: 7572218
50 DSP NM_004415.3(DSP): c.2047G> A (p.Glu683Lys) single nucleotide variant Uncertain significance rs775181391 GRCh38 Chromosome 6, 7571985: 7571985
Sources

Expression for Cardiac Arrest

About this section
Search GEO for disease gene expression data for Cardiac Arrest.
Sources

Pathways for Cardiac Arrest

About this section

Pathways related to Cardiac Arrest according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Aldosterone synthesis and secretion 37
Show member pathways
 12.37 ALB CALM1 KCNQ1 PLN RYR2 SCN5A
2
Neuroscience 4
12.29 CALM1 ENO2 S100B SCN5A
3
Cardiac conduction 66
Show member pathways
 12.29 CALM1 KCNQ1 MYBPC3 PLN RYR2 SCN5A
4
Ion channel transport 66
Show member pathways
 12.23 CALM1 PLN RYR2 TRDN
5
Myometrial Relaxation and Contraction Pathways 1
Show member pathways
 12.2 CALM1 CASQ2 PLN RYR2
6
Dilated cardiomyopathy (DCM) 37
Show member pathways
 11.89 ACE MYBPC3 PLN RYR2 TNNT2
7
Ca, cAMP and Lipid Signaling 4
11.73 ALB CALM1 PLN S100B
8
Phase 0 - rapid depolarisation 66
Show member pathways
 11.42 CALM1 KCNQ1 SCN5A
9
Antiarrhythmic Pathway, Pharmacodynamics 61
10.85 CASQ2 DSP KCNQ1 PLN RYR2 SCN5A
Sources

GO Terms for Cardiac Arrest

About this section

Cellular components related to Cardiac Arrest according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 9.71 ALB CALM1 CKB ENO2
2 Z disc GO:0030018 9.67 CASQ2 MYBPC3 RYR2 SCN5A
3 sarcomere GO:0030017 9.56 CALM1 MYBPC3 RYR2 TNNT2
4 calcium channel complex GO:0034704 9.5 CALM1 CASQ2 RYR2
5 striated muscle thin filament GO:0005865 9.49 MYBPC3 TNNT2
6 sarcoplasmic reticulum lumen GO:0033018 9.48 CASQ2 TRDN
7 cardiac myofibril GO:0097512 9.46 MYBPC3 TNNT2
8 sarcoplasmic reticulum GO:0016529 9.46 CASQ2 PLN RYR2 TRDN
9 junctional membrane complex GO:0030314 9.43 CASQ2 TRDN
10 junctional sarcoplasmic reticulum membrane GO:0014701 9.13 CASQ2 RYR2 TRDN
11 sarcoplasmic reticulum membrane GO:0033017 8.92 CASQ2 PLN RYR2 TRDN

Biological processes related to Cardiac Arrest according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.81 PLN RYR2 TRDN
2 ion transmembrane transport GO:0034220 9.8 CALM1 CASQ2 KCNQ1 RYR2 SCN5A TRDN
3 muscle contraction GO:0006936 9.78 CALM1 MYBPC3 TNNT2 TRDN
4 regulation of cardiac conduction GO:1903779 9.71 CASQ2 RYR2 TRDN
5 sarcomere organization GO:0045214 9.7 CASQ2 MYBPC3 TNNT2
6 regulation of heart contraction GO:0008016 9.69 KCNQ1 PLN TNNT2
7 regulation of heart rate by cardiac conduction GO:0086091 9.67 DSP KCNQ1 SCN5A
8 regulation of cardiac muscle contraction GO:0055117 9.65 CALM1 RYR2
9 regulation of ryanodine-sensitive calcium-release channel activity GO:0060314 9.64 CALM1 PLN
10 heart contraction GO:0060047 9.63 ACE TRDN
11 cellular response to epinephrine stimulus GO:0071872 9.63 KCNQ1 RYR2
12 negative regulation of ATPase activity GO:0032780 9.62 PLN TNNT2
13 regulation of cardiac muscle cell contraction GO:0086004 9.62 PLN SCN5A
14 regulation of membrane repolarization GO:0060306 9.61 CASQ2 KCNQ1
15 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.61 DSP RYR2
16 ventricular cardiac muscle cell action potential GO:0086005 9.61 KCNQ1